Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a fixed-dose combination dental paste consisting of chloramphenicol, tetracycline, zinc oxide, and eugenol, primarily indicated for the treatment and prevention of alveolar osteitis (dry socket). Chloramphenicol and tetracycline provide synergistic broad-spectrum antibacterial activity by inhibiting protein synthesis at the 50S and 30S ribosomal subunits, respectively, targeting pathogens common in post-extraction infections. Zinc oxide acts as a mild antiseptic and astringent base that facilitates the formation of a protective physical barrier over the exposed alveolar bone. Eugenol, a clove-derived phenolic compound, provides local analgesic and sedative effects, likely through the inhibition of prostaglandin synthesis and modulation of nerve conduction, effectively managing the acute pain characteristic of dry socket.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chloramphenicol + tetracycline + zinc oxide + eugenol.